SLNO Investors: Urgent Action Needed Before Class Action Deadline!

Soleno Therapeutics (NASDAQ: SLNO) – a biotech firm focused on Prader-Willi syndrome – is under intense scrutiny as a securities class action lawsuit deadline approaches. Investors who bought SLNO stock between March 26, 2025 and November 4, 2025 face a May 5, 2026 cutoff to seek lead plaintiff status in a class action alleging the company misled shareholders (www.prnewswire.com). This urgent deadline coincides with a critical inflection point for Soleno, as the company is expected to report earnings the very next day, on May 6, 2026 (www.ainvest.com). Below, we dive into Soleno’s fundamentals – from its dividend policy and financials to debt leverage, valuation metrics, and the array of risks and red flags – to help investors make an informed decision before the legal window closes.

Dividend Policy & Historical Yield

Soleno Therapeutics has never paid a dividend on its common stock, and management doesn’t anticipate initiating any dividends in the foreseeable future (www.sec.gov). The company’s resources have been devoted to developing and commercializing its flagship therapy rather than shareholder payouts. As a result, Soleno’s dividend yield is effectively 0.00%, with no history of distributions to investors (www.macrotrends.net). This policy is typical for clinical-stage or early-commercial biotech companies, which often reinvest any cash into R&D and commercialization efforts instead of returning it to shareholders. Investors should note that any future return on SLNO will therefore rely entirely on stock price appreciation and not on dividend income (www.sec.gov).

(AFFO/FFO metrics are not applicable here, as Soleno is not a REIT or cash-flowing property company. Instead, we consider the company’s earnings and cash flow performance below.)

Earnings and Cash Flow Performance

Soleno’s financial profile transformed in 2025 as its drug VYKAT XR (diazoxide choline extended-release) won FDA approval and entered the market for Prader-Willi syndrome. The company began recognizing product revenue in Q2 2025 and even achieved profitability by Q3 2025 (www.sec.gov). In fact, Soleno reported $66.0 million in net product revenue for Q3 2025 alone, driving a net income of about $26 million that quarter (www.sec.gov) (www.sec.gov). This was a remarkable turnaround from prior periods of heavy losses; for the first nine months of 2025, Soleno still had a cumulative net loss of $22.5 million (due to losses in early 2025 before sales ramped up) (www.sec.gov).

Despite initial profitability, it’s important to question how sustainable these earnings are. The cash flow data shows Soleno’s operating cash usage was nearly breakeven through the first three quarters of 2025 – only about $1.9 million net cash used, thanks in part to non-cash expenses (e.g. significant stock-based compensation) offsetting the $22.5M net loss (www.sec.gov). The strong cash position Soleno built in 2025 also generated substantial interest income, which actually exceeded the company’s interest expense (more on that below) (www.sec.gov) (www.sec.gov). Going forward, investors will be watching upcoming earnings (scheduled for May 6) to see if Soleno can sustain positive earnings and cash flow. Key questions include whether prescription growth for VYKAT XR can continue and whether any new costs (or legal expenses) might drag results back into the red.

Leverage and Debt Maturities

Soleno undertook minimal financial leverage relative to its cash balance. In December 2024, the company entered a loan facility with Oxford Finance for up to $200 million, but as of Q3 2025 it had drawn only $50 million from this term loan (www.sec.gov) (www.sec.gov). This $50M loan bears interest at 1-month SOFR + 5.5% and was structured with an interest-only period of 48 months followed by principal repayments (www.sec.gov) (www.sec.gov). The initial term is 5 years, meaning a maturity around late 2029, although an extension to late 2030 was possible if certain milestones were met by designated deadlines (www.sec.gov) (www.sec.gov). (Notably, one condition for extension was tied to achievements by late 2025, which the company may not have met given recent setbacks, leaving the original 2029 maturity in place.)

Aside from this secured term loan, Soleno has no significant long-term debt on its balance sheet – no convertible notes or major leases beyond standard office leases. The debt maturities are therefore modest in the near term, with the bulk of principal repayment not due for several years. At September 30, 2025, Soleno’s balance of long-term debt stood at $49.85 million (net), reflecting the $50M Oxford loan minus small unamortized costs (www.sec.gov) (www.sec.gov). Crucially, Soleno’s cash and marketable securities were around $556 million at that time (over half a billion dollars) (www.sec.gov) (www.sec.gov), meaning the company held cash reserves more than 10× the outstanding debt. This conservative leverage and long-dated maturity schedule give Soleno a financial cushion – the company is not at immediate risk of insolvency from debt, and it has ample liquidity to service obligations in the short-to-medium term.

Liquidity and Interest Coverage

Soleno’s liquidity position was very strong post-2025 fundraises. The company raised over $215 million net in a July 2025 equity offering (at the height of enthusiasm for VYKAT XR’s launch), plus additional proceeds from warrant and option exercises (www.sec.gov) (www.sec.gov). As a result, cash and equivalents swelled to $246.7 million, with another $309.4 million in marketable securities on hand by Q3 2025 (www.sec.gov). This war chest not only supports ongoing operations, but also means Soleno can easily cover its interest obligations. In the first nine months of 2025, Soleno incurred roughly $4.1 million in interest expense on its debt (www.sec.gov) – a small fraction of its cash balance. In fact, thanks to rising interest rates and the company’s large cash pile, interest income earned on its short-term investments outpaced interest expense, resulting in positive net other income (www.sec.gov) (www.sec.gov).

Traditional interest coverage ratios (EBIT/interest) are less meaningful here given Soleno’s volatile earnings. However, the company’s cash coverage is undeniably robust: even if earnings were to turn negative, Soleno could pay its annual interest cost many times over from its cash reserves alone. One important caveat is a covenant in the Oxford loan requiring Soleno to achieve minimum revenue levels starting mid-2026 (www.sec.gov). If VYKAT XR’s sales were to falter (see Risks section), a failure to meet this revenue covenant could potentially trigger a default or the need to renegotiate with lenders (www.sec.gov). In summary, liquidity is not an immediate concern – Soleno’s ~$500M liquidity buffer provides a high margin of safety for debt service and operations. The greater concern is whether the business can maintain the revenue growth needed to justify that cash burn and keep creditors satisfied.

Valuation Considerations

By late March 2026, Soleno’s market capitalization stands around $1.6–$2.0 billion (www.macrotrends.net), reflecting investor expectations for its first-in-class Prader-Willi treatment tempered by recent uncertainties. Traditional valuation metrics like P/E are in flux – trailing 12-month earnings are not meaningful given the company only just turned profitable in one quarter, and forward earnings are uncertain. Instead, price-to-sales (P/S) offers some perspective. If we annualize Soleno’s partial-year 2025 revenue (roughly $99 million in the first nine months (www.sec.gov), plus an estimated ~$50+ million in Q4), the company might have approached $150 million in sales for 2025. That implies a P/S on the order of 10× or more, which is relatively high for a commercial-stage pharma company – especially one with a single product and emerging competition. Even on an enterprise value basis (market cap minus ~$500M cash ≈ $1.1B EV), the EV/Sales multiple is around 7×. Such multiples were justifiable when VYKAT XR’s outlook appeared strong and growth was rapid, but they could prove rich if growth stalls or reverses.

For context, after FDA approval in 2023, Soleno’s stock skyrocketed from penny-stock levels to a high of over $80 per share in mid-2025 (post-reverse-split pricing) before collapsing by more than 50% amid the recent controversies (za.investing.com) (za.investing.com). The stock’s re-rating in late 2025 – it plunged over 26% on November 4, 2025 alone when troubling news emerged (www.prnewswire.com) – suggests that investors are now pricing in a much more cautious outlook. Any valuation from here hinges on key questions: Can Soleno resolve the safety concerns and regain prescriber confidence? Will VYKAT XR’s sales trajectory recover or at least stabilize? And can the company leverage its cash to create additional value (such as pipeline development or acquisitions) to diversify beyond this one drug? Until there are clearer answers, SLNO’s valuation is likely to remain volatile. Investors should be prepared for significant re-pricing risk – both to the upside (if issues are resolved or sales beat expectations) or further downside (if the situation worsens).

Risks, Red Flags, and Open Questions

Soleno is confronting a convergence of legal, commercial, and reputational risks that raise red flags for investors. Below we outline the key issues and unanswered questions facing the company:

– Alleged Clinical Data Misconduct: The core of the class action lawsuit is that Soleno made “material misstatements and/or omissions” about its Phase 3 trial for DCCR (VYKAT XR) (www.prnewswire.com). In other words, investors allege the company wasn’t fully transparent about problems in the trial program. This puts management credibility on the line – what exactly was hidden or misrepresented, and how might it impact the drug’s perceived efficacy or approval basis? The outcome of the lawsuit (which is led by a major institutional plaintiff) could potentially result in financial penalties or reforms, though it may take years to resolve. In the meantime, the mere existence of fraud allegations can damage investor trust and depress the stock.

– Drug Safety Concerns: Perhaps the most alarming red flag comes from an August 2025 short-seller report by Scorpion Capital, which raised serious safety issues with VYKAT XR. The report cited a “rapid pile-up of reports of children hospitalized for potential heart failure in recent weeks” after starting the drug (za.investing.com). Scorpion suggested VYKAT XR might face withdrawal from the market or a sharp drop in new prescriptions if these cardiac safety signals are confirmed (za.investing.com). This is a critical open question: Are adverse events emerging in the patient population, and how will regulators respond? To date, the FDA has not publicly announced any recall or black-box warning, but the company’s own Q3 report acknowledged the “disruption” in the launch trajectory after Scorpion’s findings went public (www.prnewswire.com). Investors will be watching for any updates on safety monitoring or FDA communications. A worst-case scenario (product withdrawal or usage restrictions) would be devastating for Soleno’s financials, given VYKAT XR is its sole revenue source.

– Slowing Adoption & Commercial Uncertainty: Even if VYKAT XR remains on the market, the prescription growth has been impacted. Soleno disclosed that following the short-seller’s allegations, there were higher patient discontinuation rates and fewer new patient start forms in the Prader-Willi community (www.prnewswire.com). In short, some doctors and caregivers became hesitant. Upcoming sales reports will be crucial to see if this trend persists or if the company’s outreach can reassure prescribers. The next earnings report (Q1 2026) is especially important – if management reports flat or declining sales, it will validate concerns that commercial momentum has stalled. Open question: Can Soleno counteract the negative narrative and drive adoption, or has the product’s reputation been irrevocably tarnished?

– Pipeline and Concentration Risk: Scorpion’s critique went beyond safety, calling Soleno a “one-trick pony with no meaningful assets, pipeline or scientific program.” (za.investing.com) Indeed, as of now Soleno’s fortunes are almost entirely tied to VYKAT XR. The company does not have other advanced drug candidates or diversified revenue streams to fall back on. This magnifies the impact of any single issue with VYKAT XR. If sales disappoint or the drug encounters regulatory hurdles, there is no quick alternate source of revenue to fill the gap. Open question: How will Soleno deploy its substantial cash reserves – will it invest in expanding its pipeline (organically or via acquisitions) to diversify risk, or will that cash be eroded by ongoing expenses if VYKAT XR underperforms?

– Patent Expiry and Competitive Threats: Another red flag is the intellectual property timeline. VYKAT XR’s core patent is reportedly set to expire in 2026, making it essentially a reformulation of a half-century-old drug (diazoxide) with limited exclusivity remaining (za.investing.com). This means that within a short time, generic competition or alternative formulations could emerge, potentially undercutting Soleno’s pricing power. Investors need to consider how Soleno will protect or extend its franchise – for example, through new patents on dosing or new indications – otherwise the window for profitability may be narrow. Additionally, competitors targeting Prader-Willi syndrome (or its symptoms) could seize on Soleno’s turmoil to advance their own treatments. The ghost of Zafgen (a previous PWS drug developer that failed after safety issues) looms large (za.investing.com); Soleno must avoid a similar fate. Open question: Can Soleno address the patent cliff or differentiate VYKAT XR enough to maintain a market edge post-2026?

– Debt Covenants and Financial Flexibility: As mentioned, Soleno’s loan agreement imposes a minimum revenue covenant effective mid-2026 (www.sec.gov). If the safety scare leads to significantly lower sales than expected, Soleno might technically breach this covenant. While the company’s cash could cover the $50M debt, a covenant breach could give the lender leverage – possibly demanding repayment or refinancing under less favorable terms (www.sec.gov). This is something to monitor in the coming quarters. So far Soleno has not drawn additional tranches of the Oxford loan (likely to avoid interest and covenants until needed) (www.sec.gov) (www.sec.gov). But if sales fall short and the company decides to lean on its cash cushion to fund operations (rather than borrowing more), that cash burn will reduce the very safety net investors are counting on. Open question: Will Soleno’s cash last long enough to weather this storm and, if needed, support a pivot or relaunch strategy?

In light of these risks, it’s clear why investors are urged to take action by the class action deadline. Those who believe they were misled and suffered losses have the option to join the lawsuit or even pursue lead plaintiff status by May 5, 2026 (www.prnewswire.com). On the other hand, some investors may simply choose to reassess their holdings – the coming weeks and months (with the lawsuit proceeding and new financial data releasing) represent a critical period for deciding whether to hold, sell, or seek legal recourse. There are multiple open questions that only time and further disclosures will answer. Until we see how Soleno management responds – both in court and in the marketplace – uncertainty will remain exceptionally high.

—

Bottom Line: Soleno Therapeutics delivered an initially promising commercial launch with VYKAT XR, but that success is now clouded by allegations of fraud and safety problems. The company’s fundamentals (no dividend, strong cash, manageable debt) provide some stability, yet the valuation and future prospects hinge on resolving the current crisis of confidence. With a class action lawsuit underway and a pivotal earnings report on deck, SLNO investors must stay vigilant. The clock is ticking on the legal deadline – and perhaps on Soleno’s window to prove that VYKAT XR can safely fulfill its potential. In this tense moment, conducting due diligence and considering one’s options (including legal rights) is not just prudent – it’s urgent. (www.prnewswire.com) (www.prnewswire.com)

For informational purposes only; not investment advice.